225 related articles for article (PubMed ID: 11503765)
1. Opioid drugs in maintenance and detoxification treatment of opiate addiction; Substance Abuse and Mental Health Services Administration, HHS. Final rule.
Fed Regist; 2001 Jan; 66(11):4076-102. PubMed ID: 11503765
[TBL] [Abstract][Full Text] [Related]
2. Methadone in maintenance treatment of narcotic addicts; joint revision of conditions for use; interim maintenance treatment; human immunodeficiency virus disease counseling--FDA and SAMHSA. Final rule.
Fed Regist; 1993 Jan; 58(3):495-9. PubMed ID: 10171334
[TBL] [Abstract][Full Text] [Related]
3. Buprenorphine for office-based treatment of patients with opioid addiction.
Manlandro JJ
J Am Osteopath Assoc; 2005 Jun; 105(6 Suppl 3):S8-13. PubMed ID: 16118361
[TBL] [Abstract][Full Text] [Related]
4. New federal regulations for improving quality in opioid treatment programs.
Pelletier LR; Hoffman JA
J Healthc Qual; 2001; 23(6):29-34. PubMed ID: 23413476
[TBL] [Abstract][Full Text] [Related]
5. Opioid drugs in maintenance and detoxification treatment of opiate addiction; addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications. Interim final rule.
Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services
Fed Regist; 2003 May; 68(99):27937-9. PubMed ID: 12762334
[TBL] [Abstract][Full Text] [Related]
6. Treatment options for opiate addiction.
J Ky Med Assoc; 2004 May; 102(5):221-4. PubMed ID: 15152448
[No Abstract] [Full Text] [Related]
7. SAMHSA outlines how to treat addiction to prescription painkillers and heroin in physicians' offices.
Conn Med; 2003 Feb; 67(2):103-4. PubMed ID: 12664838
[No Abstract] [Full Text] [Related]
8. Opioid drugs in maintenance and detoxification treatment of opiate addiction; proposed modification of dispensing restrictions for buprenorphine and buprenorphine combination as used in approved opioid treatment medications. Final rule.
Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (HHS)
Fed Regist; 2012 Dec; 77(235):72752-61. PubMed ID: 23227572
[TBL] [Abstract][Full Text] [Related]
9. Substance Abuse and Mental Health Services Administration; requirements applicable to protection and advocacy of individuals with mental illness; final rule--Center for Mental Health Services, SAMHSA. Final rule.
Fed Regist; 1997 Oct; 62(199):53548-71. PubMed ID: 10177296
[TBL] [Abstract][Full Text] [Related]
10. Using buprenorphine for outpatient opioid detoxification.
Manlandro JJ
J Am Osteopath Assoc; 2007 Sep; 107(9 Suppl 5):ES11-6. PubMed ID: 17908825
[TBL] [Abstract][Full Text] [Related]
11. Authority for practitioners to dispense or prescribe approved narcotic controlled substances for maintenance or detoxification treatment. Final rule.
Drug Enforcement Administration (DEA), Justice
Fed Regist; 2005 Jun; 70(120):36338-44. PubMed ID: 15973789
[TBL] [Abstract][Full Text] [Related]
12. Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification.
Masson CL; Barnett PG; Sees KL; Delucchi KL; Rosen A; Wong W; Hall SM
Addiction; 2004 Jun; 99(6):718-26. PubMed ID: 15139870
[TBL] [Abstract][Full Text] [Related]
13. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
[TBL] [Abstract][Full Text] [Related]
14. Opiate addiction in China: current situation and treatments.
Tang YL; Zhao D; Zhao C; Cubells JF
Addiction; 2006 May; 101(5):657-65. PubMed ID: 16669899
[TBL] [Abstract][Full Text] [Related]
15. Bupreorphine:a new pharmacotherapy for opioid addictions treatment.
Stock C; Shum JH
J Pain Palliat Care Pharmacother; 2004; 18(3):35-54. PubMed ID: 15364630
[TBL] [Abstract][Full Text] [Related]
16. The role of the National Institute on Drug Abuse in the development of naltrexone.
Ginzburg HM; Glass WJ
J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):4-6. PubMed ID: 6088469
[TBL] [Abstract][Full Text] [Related]
17. Consensus statement on office-based treatment of opioid dependence using buprenorphine.
Fiellin DA; Kleber H; Trumble-Hejduk JG; McLellan AT; Kosten TR
J Subst Abuse Treat; 2004 Sep; 27(2):153-9. PubMed ID: 15450648
[TBL] [Abstract][Full Text] [Related]
18. The costs of pursuing accreditation for methadone treatment sites: results from a national study.
Zarkin GA; Dunlap LJ; Homsi G
Eval Rev; 2006 Apr; 30(2):119-38. PubMed ID: 16492995
[TBL] [Abstract][Full Text] [Related]
19. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
Turner BJ; Laine C; Lin YT; Lynch K
Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826
[TBL] [Abstract][Full Text] [Related]
20. Treating opioid dependence. Growing implications for primary care.
Krantz MJ; Mehler PS
Arch Intern Med; 2004 Feb; 164(3):277-88. PubMed ID: 14769623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
